• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety and Efficacy of Vadadustat Once Daily and Three Times Weekly in Patients With Dialysis-Dependent CKD With Anemia.

作者信息

Kooienga Laura, Burke Steven, Kathresal Amarnath, Luo Wenli, Yang Zhihui, Zhang Zhiqun, Zwiech Rafal, Hernandez German T

机构信息

Colorado Kidney Care, Aurora, Colorado.

Akebia Therapeutics, Inc., Cambridge, Massachusetts.

出版信息

Kidney360. 2024 Nov 1;5(11):1652-1661. doi: 10.34067/KID.0000000567. Epub 2024 Sep 4.

DOI:10.34067/KID.0000000567
PMID:39231617
Abstract
摘要

相似文献

1
Safety and Efficacy of Vadadustat Once Daily and Three Times Weekly in Patients With Dialysis-Dependent CKD With Anemia.每日一次和每周三次服用vadadustat对透析依赖型慢性肾脏病贫血患者的安全性和有效性
Kidney360. 2024 Nov 1;5(11):1652-1661. doi: 10.34067/KID.0000000567. Epub 2024 Sep 4.
2
A randomized trial to evaluate the pharmacokinetics, pharmacodynamics, and safety of vadadustat in patients with anemia associated with chronic kidney disease receiving hemodialysis.一项评估vadadustat在接受血液透析的慢性肾脏病贫血患者中的药代动力学、药效学及安全性的随机试验。
BMC Nephrol. 2025 Aug 11;26(1):453. doi: 10.1186/s12882-025-04367-x.
3
Real-World Safety and Effectiveness of Vadadustat in Patients with Chronic Kidney Disease-Related Anemia: Interim Analysis of Postmarketing Surveillance in Japan.瓦达他司他在慢性肾脏病相关性贫血患者中的真实世界安全性和有效性：日本上市后监测的中期分析
Adv Ther. 2025 Jul 11. doi: 10.1007/s12325-025-03272-x.
4
Vadadustat Three Times Weekly in Patients With Anemia Due to Dialysis-Dependent CKD.对于因依赖透析的慢性肾脏病导致贫血的患者，每周三次使用vadadustat治疗。
Am J Kidney Dis. 2025 Apr;85(4):454-464.e1. doi: 10.1053/j.ajkd.2024.09.006. Epub 2024 Nov 7.
5
Unveiling Vadadustat: Comprehensive Review of its Chemistry, Pharmacology, Bioanalysis, and Patent Landscape as a Novel HIF-PH Inhibitor.揭开伐达他司他的面纱：作为一种新型低氧诱导因子脯氨酰羟化酶（HIF-PH）抑制剂的化学、药理学、生物分析及专利情况的全面综述
Curr Top Med Chem. 2025 Jul 22. doi: 10.2174/0115680266366384250716121432.
6
Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review.甲氧基聚乙二醇-促红细胞生成素β与阿法达贝泊汀治疗非透析依赖型慢性肾脏病贫血的系统评价
Int J Clin Pharm. 2014 Dec;36(6):1115-25. doi: 10.1007/s11096-014-0023-x. Epub 2014 Oct 7.
7
Vascular Access Thrombosis Events in Patients With Dialysis-Dependent CKD Treated With Vadadustat or Darbepoetin Alfa: The INNOVATE Trial Program.使用瓦达司他或阿法达贝泊汀治疗的依赖透析的慢性肾脏病患者的血管通路血栓形成事件：INNOVATE试验项目
Kidney Med. 2025 Mar 19;7(5):100997. doi: 10.1016/j.xkme.2025.100997. eCollection 2025 May.
8
Clinical Pharmacokinetics and Pharmacodynamics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.口服低氧诱导因子脯氨酰羟化酶抑制剂瓦他司他的临床药代动力学和药效学
Eur J Drug Metab Pharmacokinet. 2025 May 2. doi: 10.1007/s13318-025-00947-2.
9
Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients.伐达他司，一种口服低氧诱导因子脯氨酰羟化酶抑制剂，用于治疗慢性肾脏病贫血：在日本患者中进行的两项随机2期试验。
Nephrol Dial Transplant. 2020 Jul 28. doi: 10.1093/ndt/gfaa060.
10
Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.维达列汀治疗透析患者贫血的安全性和疗效。
N Engl J Med. 2021 Apr 29;384(17):1601-1612. doi: 10.1056/NEJMoa2025956.

本文引用的文献

1
Daprodustat and Heart Failure in CKD.达普司他与慢性肾脏病相关心力衰竭。
J Am Soc Nephrol. 2024 May 1;35(5):607-617. doi: 10.1681/ASN.0000000000000321. Epub 2024 Feb 22.
2
Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis.vadadustat 治疗腹膜透析的透析依赖型慢性肾脏病患者的贫血。
Nephrol Dial Transplant. 2023 Sep 29;38(10):2358-2367. doi: 10.1093/ndt/gfad074.
3
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial.
每周三次给予 daprodustat 与常规促红细胞生成素治疗血液透析患者贫血的疗效比较：ASCEND-TD 研究：一项 3 期随机、双盲、非劣效性试验
Clin J Am Soc Nephrol. 2022 Sep;17(9):1325-1336. doi: 10.2215/CJN.00550122. Epub 2022 Aug 2.
4
Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.罗沙司他对比促红细胞生成素α治疗透析患者慢性肾脏病相关贫血的随机 3 期 ROCKIES 研究结果。
J Am Soc Nephrol. 2022 Apr;33(4):850-866. doi: 10.1681/ASN.2020111638.
5
Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.达普司他用于治疗未接受透析患者的贫血
N Engl J Med. 2021 Dec 16;385(25):2313-2324. doi: 10.1056/NEJMoa2113380. Epub 2021 Nov 5.
6
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.达普司他用于治疗透析患者的贫血
N Engl J Med. 2021 Dec 16;385(25):2325-2335. doi: 10.1056/NEJMoa2113379. Epub 2021 Nov 5.
7
Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.维达列汀治疗透析患者贫血的安全性和疗效。
N Engl J Med. 2021 Apr 29;384(17):1601-1612. doi: 10.1056/NEJMoa2025956.
8
Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.vadadustat 治疗贫血及非透析依赖性慢性肾脏病患者的疗效。
N Engl J Med. 2021 Apr 29;384(17):1589-1600. doi: 10.1056/NEJMoa2035938.
9
Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents.慢性肾脏病中的贫血：从病理生理学到当前治疗方法，再到未来治疗药物
Front Med (Lausanne). 2021 Mar 26;8:642296. doi: 10.3389/fmed.2021.642296. eCollection 2021.
10
Anemia management for home dialysis including the new US public policy initiative.家庭透析的贫血管理，包括美国新的公共政策倡议。
Kidney Int Suppl (2011). 2021 Apr;11(1):59-69. doi: 10.1016/j.kisu.2020.12.005. Epub 2021 Mar 18.